Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 crawled date : 2021 - 10 - 27 save search
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in ChinaCPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals
Published: 2021-10-27 (Crawled : 21:00) - biospace.com/
CRVS | $1.58 3.27% 3.16% 91K
|
Health Technology
|
| O: -2.45%
H: 5.25%
C: 4.11%
phase 1 china trial approval
Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.91%
H: 0.06%
C: -1.04%
KYMR | $35.18 -1.48% -1.51% 380K
|
Health Technology
|
| O: -0.5%
H: 3.25%
C: 0.66%
phase 1 positive trial
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
MNPR | $0.63 -3.08% -3.17% 39K
|
Health Technology
|
| O: 4.88%
H: 7.64%
C: 3.31%
treatment phase 1 phase 1b trial phase 2b soft tissue
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
Published: 2021-10-27 (Crawled : 13:00) - biospace.com/
NRIX 6 d | $13.73 -2.83% -2.91% 520K
|
Health Technology
|
| O: 9.5%
H: 15.97%
C: 8.74%
phase 1 trial phase 1b t-cell
Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor Malignancies
Published: 2021-10-27 (Crawled : 13:00) - biospace.com/
KZR | $0.8016 -2.95% -3.04% 420K
|
Health Technology
|
| O: 0.83%
H: 0.0%
C: -6.36%
phase 1 trial solid tumors phase 2
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
Published: 2021-10-27 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $38.72 -2.25% -0.28% 970K
|
Health Technology
|
| O: 0.21%
H: 0.1%
C: -3.26%
treatment phase 1 therapy antibody trial phase 1b enroll
Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935
Published: 2021-10-27 (Crawled : 11:00) - prnewswire.com
IMUX | $1.24 0.0% 130K
|
Health Technology
|
| O: -1.5%
H: 4.23%
C: 2.0%
psoriasis ongoing phase 1 trial phase 2 enroll phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.